<div id="firstBodyDiv" data-bind-html-content-type="article" data-bind-html-compile="article.body" data-first-article-body="
This is not a cure. But it’s one of the latest gains in a targeted response to cancer, which could open the door to producing new treatments for thousands of patients with advanced breast cancer.
So far, breast cancers have been classified as either HER2 positive – containing cancer cells It contains more protein than normal – OHR2 negative.
Doctors who announced the new success, on Sunday, said that it would make the HER2-low class – a new category to guide treatment. breast cancer.
About half of patients with late-stage breast cancer are categorized as HER2 negative and may in fact be HER2 low and qualify for the drug.
property is "Herto"A combination of chemotherapy and antibodies injected into a vein finds and blocks the HER2 protein from cancer cells, while also releasing a powerful cancer-killing chemical into those cells.
and belongs Medicine New to a relatively new class of drugs called antibody conjugates.
The drug has already been approved for HER2-positive breast cancer, and in April the US Food and Drug Administration granted it status of achievement for this new group of patients.
In the new study, the drug extended the length of time patients lived without developing a disease cancer They have improved survival compared to patients who received regular chemotherapy.
And compared the study "Herto" With standard chemotherapy in about 500 patients with low HER2 breast cancer that has either spread or cannot be treated with surgery.
and stop real estate The cancer progressed for about 10 months, compared to about 5 and a half months in the group receiving regular care.
“>
This is not a cure. But it’s one of the latest gains in a targeted response to cancer, which could open the door to producing new treatments for thousands of patients with advanced breast cancer.
So far, breast cancers have been classified as either HER2 positive – containing cancer cells It contains more protein than normal – OHR2 negative.
Doctors who announced the new success, on Sunday, said that it would make the HER2-low class – a new category to guide treatment. breast cancer.
About half of patients with late-stage breast cancer are categorized as HER2 negative and may in fact be HER2 low and qualify for the drug.
The drug, Inherto, is a combination of chemotherapy and antibodies injected into a vein that finds and blocks the HER2 protein from cancer cells, while also releasing a powerful cancer-killing chemical into those cells.
and belongs Medicine New to a relatively new class of drugs called antibody conjugates.
The drug has already been approved for HER2-positive breast cancer, and in April the US Food and Drug Administration granted it status of achievement for this new group of patients.
In the new study, the drug extended the length of time patients lived without developing a disease cancer They have improved survival compared to patients who received regular chemotherapy.
The study compared Inherto with standard chemotherapy in nearly 500 patients with low HER2 breast cancer that had either spread or could not be treated with surgery.
and stop real estate The cancer progressed for about 10 months, compared to about 5 and a half months in the group receiving regular care.